![Francesco Maria Lavino](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Francesco Maria Lavino
Directeur Général chez
F2G Ltd.
Profil
Mr. Francesco M.
Lavino is a Chief Executive Officer & Director at F2G Ltd. and a President & Director at F2g Inc. He is on the Board of Directors at F2G Ltd. and F2g Inc. Mr. Lavino was previously employed as a Chief Commercial Officer by Nabriva Therapeutics Plc, an Associate Vice President by Merck & Co., Inc., a Vice President-International Marketing by Cubist Pharmaceuticals LLC, and an Executive Director by Merck & Co., Inc. He received his undergraduate degree from Università degli Studi di Napoli Federico II and an MBA from SDA Bocconi School of Management.
Postes actifs de Francesco Maria Lavino
| Sociétés | Poste | Début |
|---|---|---|
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Directeur Général | 12/04/2021 |
F2g Inc.
 F2g Inc. Pharmaceuticals: OtherHealth Technology F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | President | - |
Anciens postes connus de Francesco Maria Lavino
| Sociétés | Poste | Fin |
|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | 01/07/2017 |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/09/2015 |
| MERCK & CO., INC. | Directeur/Membre du Conseil | 01/11/2013 |
| NABRIVA THERAPEUTICS PLC | Corporate Officer/Principal | - |
Formation de Francesco Maria Lavino
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Health Technology |
Università degli Studi di Napoli Federico II
 Università degli Studi di Napoli Federico II Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SDA Bocconi School of Management
 SDA Bocconi School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nabriva Therapeutics Plc
 Nabriva Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the research, development, and commercialization of novel anti-infective agents | Health Technology |
F2g Inc.
F2g Inc. Pharmaceuticals: OtherHealth Technology F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Health Technology |
